

**Scenario: Understanding of LEAN writing principles and AMA style, English language facility, ability to integrate data from multiple sources and interpret it clearly, accurately, and concisely.**

Using the data in the 5 adverse event tables below, re-write the adverse event summary using LEAN writing principles and following the writing style of the AMA Manual of Style and English language grammar, spelling, and syntax.

*This was a double-blinded, ascending single dose pharmacokinetic study of oral RWJ XXX in healthy adult male volunteers.*

### **Brief summary of AEs**

There were not any deaths or serious adverse events reported during this study. Of the 49 subjects who received active RWJXXX, 34 (69.4%) subjects reported at least one adverse event, with a total of 58 adverse events reported. Of the 21 subjects who received placebo, 7 (33.3%) reported at least one adverse event, with a total of 13 adverse events reported. Overall, the most commonly reported adverse events for all subjects were: hypoesthesia (15.5%), dizziness (15.5%), euphoria (14.1%), paresthesia (8.5%), headache (5.6%), mouth dry (4.2%), nausea (4.2%), influenza-like symptoms (2.8%), temperature changed sensation (2.8.5), and throat tightness (2.8%). There was only a single incidence of all other reported adverse events. Three (3) subjects with 3 adverse events (influenza-like symptoms, headache, back pain) required treatment with concomitant medication. These medications are listed in Table 10.2.1.

Although statistical analysis was not performed, there appears to be a dose dependent relationship in the number and type of adverse events reported; Table 12.2.2.3 displays the number of adverse events that occurred in each dose group. Of the 11 adverse events that were described as not related to the study drug, 9 adverse events occurred in the 400 mg or lower dose groups. Of the 47 adverse events that were described as possibly related to the study drug, 43 adverse events occurred in the 750 mg or higher dose groups. Table 12.2.2.5 displays the number of adverse events by dose and relationship to study drug.

The majority (25) of the 43 adverse events described as possibly related to the study drug that occurred in the 750 mg dose group or higher were central and peripheral nervous system disorders, including dizziness, headache, hypoesthesia, and paresthesia. Additionally, there were 10 psychiatric disorder adverse events (agitation, euphoria, and somnolence) and 4 gastrointestinal system disorder adverse events (mouth dry and nausea) in the group. Statistical

analysis was not performed on these data and therefore the significance of these trends cannot be determined.

### Display of adverse events

**Table 12.2.2-1: Number of Subjects With and Without Adverse Events By Body System and Dose Group; Active RWJXXX and Placebo**

Body System Adverse Event	Dose Group (Active RWJXXX)							Placebo n (%)	Total n (%)
	100 mg n (%)	250 mg n (%)	400 mg n (%)	750 mg n (%)	1000 mg n (%)	1250 mg n (%)	1500 mg n (%)		
Number of Subjects Who Received Medication	7 (100)	7 (100)	7 (100)	7 (100)	7 (100)	7 (100)	7 (100)	21 (100)	70 (100)
Number of Subjects With Adverse Events	3 (42.9)	4 (57.1)	3 (42.9)	5 (71.4)	7 (100)	6 (85.7)	6 (85.7)	7 (33.3)	41 (58.6)
Number of Subjects With No Adverse Events	4 (57.1)	3 (42.9)	4 (57.1)	2 (28.6)	0 (0)	1 (14.3)	1 (14.3)	14 (66.7)	29 (41.4)
<b>Body as a Whole</b>	<b>1 (14.3)</b>	<b>1 (14.3)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>1 (14.3)</b>	<b>0 (0)</b>	<b>1 (14.3)</b>	<b>2 (9.5)</b>	<b>6 (8.6)</b>
Asthenia	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (14.3)	0 (0)	1 (1.4)
Back Pain	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4.8)	1 (1.4)
Influenza-Like Symptoms	1 (14.3)	1 (14.3)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2.9)
Temperature Changed Sensation	0 (0)	0 (0)	0 (0)	0 (0)	1 (14.3)	0 (0)	0 (0)	1 (4.8)	2 (2.9)
<b>Cardiovascular Disorders, General</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>1 (14.3)</b>	<b>0 (0)</b>	<b>1 (1.4)</b>
Hypotension	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (14.3)	0 (0)	1 (1.4)
<b>Central &amp; Peripheral Nervous System Disorders</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>1 (14.3)</b>	<b>2 (28.6)</b>	<b>5 (71.4)</b>	<b>5 (71.4)</b>	<b>5 (71.4)</b>	<b>4 (19.0)</b>	<b>22 (31.4)</b>
Dizziness	0 (0)	0 (0)	0 (0)	1 (14.3)	3 (42.9)	2 (28.6)	2 (28.6)	2 (9.5)	10 (14.3)
Headache	0 (0)	0 (0)	1 (14.3)	1 (14.3)	0 (0)	0 (0)	1 (14.3)	1 (4.8)	4 (5.7)
Hypoesthesia	0 (0)	0 (0)	0 (0)	0 (0)	4 (57.1)	3 (42.9)	3 (42.9)	1 (4.8)	11 (15.7)
Paraesthesia	0 (0)	0 (0)	0 (0)	0 (0)	1 (14.3)	2 (28.6)	1 (14.3)	1 (4.8)	5 (7.1)
<b>Gastro-intestinal System Disorders</b>	<b>0 (0)</b>	<b>1 (14.3)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>3 (42.9)</b>	<b>2 (9.5)</b>	<b>6 (8.6)</b>
Abdominal Pain	0 (0)	1 (14.3)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1.4)
Glossitis	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4.8)	1 (1.4)
Mouth Dry	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (42.9)	0 (0)	3 (4.3)
Nausea	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (14.3)	2 (9.5)	3 (4.3)
<b>Hearing &amp; Vestibular Disorders</b>	<b>0 (0)</b>	<b>1 (14.3)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>1 (1.4)</b>
Ear Disorder Nos	0 (0)	1 (14.3)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1.4)
<b>Musculo-skeletal System Disorders</b>	<b>1 (14.3)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>1 (14.3)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>2 (2.9)</b>
Arthralgia	1 (14.3)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1.4)
Skeletal Pain	0 (0)	0 (0)	0 (0)	0 (0)	1 (14.3)	0 (0)	0 (0)	0 (0)	1 (1.4)
<b>Psychiatric Disorders</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>2 (28.6)</b>	<b>4 (57.1)</b>	<b>3 (42.9)</b>	<b>1 (14.3)</b>	<b>2 (28.6)</b>	<b>1 (4.8)</b>	<b>13 (18.6)</b>
Agitation	0 (0)	0 (0)	0 (0)	0 (0)	1 (14.3)	0 (0)	0 (0)	0 (0)	1 (1.4)
Euphoria	0 (0)	0 (0)	2 (28.6)	4 (57.1)	2 (28.6)	0 (0)	2 (28.6)	0 (0)	10 (14.3)
Nervousness	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4.8)	1 (1.4)
Somnolence	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (14.3)	0 (0)	0 (0)	1 (1.4)
<b>Respiratory System Disorder</b>	<b>0 (0)</b>	<b>1 (14.3)</b>	<b>1 (14.3)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>2 (28.6)</b>	<b>1 (4.8)</b>	<b>5 (7.1)</b>
Coughing	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4.8)	1 (1.4)
Dyspnoea	0 (0)	1 (14.3)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1.4)
Sinusitis	0 (0)	0 (0)	1 (14.3)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1.4)
Throat Tightness	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (28.6)	0 (0)	2 (2.9)
<b>Secondary Terms</b>	<b>1 (14.3)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>1 (1.4)</b>
Cyst Nos	1 (14.3)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1.4)
<b>Skin &amp; Appendages Disorders</b>	<b>0 (0)</b>	<b>1 (14.3)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>1 (1.4)</b>
Pruritis	0 (0)	1 (14.3)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1.4)
<b>Vision Disorders</b>	<b>0 (0)</b>	<b>1 (14.3)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>1 (1.4)</b>
Blepharitis	0 (0)	1 (14.3)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1.4)

Source: Tables 14.2, 14.3, and 14.4, and Appendix 16.1.7

**Table 12.2.2-2: Number of Subjects With and Without Adverse Events By Body System and Dose Group; Active RWJXXX (All Dose Groups Combined) and Placebo**

Body System Adverse Event	Active RWJXXX (All Dose Groups) n (%)	Placebo n (%)	Total n (%)
Number of Subjects Who Received Medication	49 (100)	21 (100)	70 (100)
Number of Subjects With Adverse Events	34 (69.4)	7 (33.3)	41 (58.6)
Number of Subjects With No Adverse Events	15 (30.6)	14 (66.7)	29 (41.4)
<b>Body as a Whole</b>	<b>4 (8.2)</b>	<b>2 (9.5)</b>	<b>6 (8.6)</b>
Asthenia	1 (2.0)	0 (0)	1 (1.4)
Back Pain	0 (0)	1 (4.8)	1 (1.4)
Influenza-Like Symptoms	2 (4.1)	0 (0)	2 (2.9)
Temperature Changed Sensation	1 (2.0)	1 (4.8)	2 (2.9)
<b>Cardiovascular Disorders, General</b>	<b>1 (2.0)</b>	<b>0 (0)</b>	<b>1 (1.4)</b>
Hypotension	1 (2.0)	0 (0)	1 (1.4)
<b>Central &amp; Peripheral Nervous System Disorders</b>	<b>18 (36.7)</b>	<b>4 (19.0)</b>	<b>22 (31.4)</b>
Dizziness	8 (16.3)	2 (9.5)	10 (14.3)
Headache	3 (6.1)	1 (4.8)	4 (5.7)
Hypoaesthesia	10 (20.4)	1 (4.8)	11 (15.7)
Paraesthesia	4 (8.2)	1 (4.8)	5 (7.1)
<b>Gastro-intestinal System Disorders</b>	<b>4 (8.2)</b>	<b>2 (9.5)</b>	<b>6 (8.6)</b>
Abdominal Pain	1 (2.0)	0 (0)	1 (1.4)
Glossitis	0 (0)	1 (4.8)	1 (1.4)
Mouth Dry	3 (6.1)	0 (0)	3 (4.3)
Nausea	1 (2.0)	2 (9.5)	3 (4.3)
<b>Hearing &amp; Vestibular Disorders</b>	<b>1 (2.0)</b>	<b>0 (0)</b>	<b>1 (1.4)</b>
Ear Disorder Nos	1 (2.0)	0 (0)	1 (1.4)
<b>Musculo-skeletal System Disorders</b>	<b>2 (4.1)</b>	<b>0 (0)</b>	<b>2 (2.9)</b>
Arthralgia	1 (2.0)	0 (0)	1 (1.4)
Skeletal Pain	1 (2.0)	0 (0)	1 (1.4)
<b>Psychiatric Disorders</b>	<b>12 (24.5)</b>	<b>1 (4.8)</b>	<b>13 (18.6)</b>
Agitation	1 (2.0)	0 (0)	1 (1.4)
Euphoria	10 (20.4)	0 (0)	10 (14.3)
Nervousness	0 (0)	1 (4.8)	1 (1.4)
Somnolence	1 (2.0)	0 (0)	1 (1.4)
<b>Respiratory System Disorder</b>	<b>4 (8.2)</b>	<b>1 (4.8)</b>	<b>5 (7.1)</b>
Coughing	0 (0)	1 (4.8)	1 (1.4)
Dyspnoea	1 (2.0)	0 (0)	1 (1.4)
Sinusitis	1 (2.0)	0 (0)	1 (1.4)
Throat Tightness	2 (4.1)	0 (0)	2 (2.9)
<b>Secondary Terms</b>	<b>1 (2.0)</b>	<b>0 (0)</b>	<b>1 (1.4)</b>
Cyst Nos	1 (2.0)	0 (0)	1 (1.4)
<b>Skin &amp; Appendages Disorders</b>	<b>1 (2.0)</b>	<b>0 (0)</b>	<b>1 (1.4)</b>
Pruritis	1 (2.0)	0 (0)	1 (1.4)
<b>Vision Disorders</b>	<b>1 (2.0)</b>	<b>0 (0)</b>	<b>1 (1.4)</b>
Blepharitis	1 (2.0)	0 (0)	1 (1.4)

ce: Tables 14.2, 14.3, and 14.4, and Appendix 16.1.7

**Table 12.2.2-3: Number of Adverse Events By Dose Group and Body System; Active RWJXXX and Placebo**

Body System Adverse Event	Dose Group (Active RWJXXX)							Placebo n (%)	Total n (%)
	100 mg n (%)	250 mg n (%)	400 mg n (%)	750 mg n (%)	1000 mg n (%)	1250 mg n (%)	1500 mg n (%)		
Number of Adverse Events	3 (100)	6 (100)	4 (100)	6 (100)	14 (100)	8 (100)	17 (100)	13 (100)	71 (100)
<b>Body as a Whole</b>	<b>1 (33.3)</b>	<b>1 (16.7)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>1 (7.1)</b>	<b>0 (0)</b>	<b>1 (5.9)</b>	<b>2 (15.4)</b>	<b>6 (8.5)</b>
Asthenia	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (5.9)	0 (0)	1 (1.4)
Back Pain	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (7.7)	1 (1.4)
Influenza-Like Symptoms	1 (33.3)	1 (16.7)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2.8)
Temperature Changed Sensation	0 (0)	0 (0)	0 (0)	0 (0)	1 (7.1)	0 (0)	0 (0)	1 (7.7)	2 (2.8)
<b>Cardiovascular Disorders, General</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>1 (5.9)</b>	<b>0 (0)</b>	<b>1 (1.4)</b>
Hypotension	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (5.9)	0 (0)	1 (1.4)
<b>Central &amp; Peripheral Nervous System Disorders</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>1 (25.0)</b>	<b>2 (33.3)</b>	<b>9 (64.3)</b>	<b>7 (87.5)</b>	<b>7 (41.2)</b>	<b>6 (46.2)</b>	<b>32 (45.1)</b>
Dizziness	0 (0)	0 (0)	0 (0)	1 (16.7)	3 (21.4)	2 (25.0)	2 (11.8)	3 (23.1)	11 (15.5)
Headache	0 (0)	0 (0)	1 (25.0)	1 (16.7)	0 (0)	0 (0)	1 (5.9)	1 (7.7)	4 (5.6)
Hypoesthesia	0 (0)	0 (0)	0 (0)	0 (0)	4 (28.6)	3 (37.5)	3 (17.6)	1 (7.7)	11 (15.5)
Paraesthesia	0 (0)	0 (0)	0 (0)	0 (0)	2 (14.3)	2 (25.0)	1 (5.9)	1 (7.7)	6 (8.5)
<b>Gastro-intestinal System Disorders</b>	<b>0 (0)</b>	<b>1 (16.7)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>4 (23.5)</b>	<b>3 (23.1)</b>	<b>8 (11.3)</b>
Abdominal Pain	0 (0)	1 (16.7)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1.4)
Glossitis	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (7.7)	1 (1.4)
Mouth Dry	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (17.6)	0 (0)	3 (4.2)
Nausea	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (5.9)	2 (15.4)	3 (4.2)
<b>Hearing &amp; Vestibular Disorders</b>	<b>0 (0)</b>	<b>1 (16.7)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>1 (1.4)</b>
Ear Disorder Nos	0 (0)	1 (16.7)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1.4)
<b>Musculo-skeletal System Disorders</b>	<b>1 (33.3)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>1 (7.1)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>2 (2.8)</b>
Arthralgia	1 (33.3)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1.4)
Skeletal Pain	0 (0)	0 (0)	0 (0)	0 (0)	1 (7.1)	0 (0)	0 (0)	0 (0)	1 (1.4)
<b>Psychiatric Disorders</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>2 (50.0)</b>	<b>4 (66.7)</b>	<b>3 (21.4)</b>	<b>1 (12.5)</b>	<b>2 (11.8)</b>	<b>1 (7.7)</b>	<b>13 (18.3)</b>
Agitation	0 (0)	0 (0)	0 (0)	0 (0)	1 (7.1)	0 (0)	0 (0)	0 (0)	1 (1.4)
Euphoria	0 (0)	0 (0)	2 (50.0)	4 (66.7)	2 (14.3)	0 (0)	2 (11.8)	0 (0)	10 (14.1)
Nervousness	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (7.7)	1 (1.4)
Somnolence	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (12.5)	0 (0)	0 (0)	1 (1.4)
<b>Respiratory System Disorder</b>	<b>0 (0)</b>	<b>1 (16.7)</b>	<b>1 (25.0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>2 (11.8)</b>	<b>1 (7.7)</b>	<b>5 (7.0)</b>
Coughing	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (7.7)	1 (1.4)
Dyspnoea	0 (0)	1 (16.7)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1.4)
Sinusitis	0 (0)	0 (0)	1 (25.0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1.4)
Throat Tightness	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (11.8)	0 (0)	2 (2.8)
<b>Secondary Terms</b>	<b>1 (33.3)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>1 (1.4)</b>
Cyst Nos	1 (33.3)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1.4)
<b>Skin &amp; Appendages Disorders</b>	<b>0 (0)</b>	<b>1 (16.7)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>1 (1.4)</b>
Pruritis	0 (0)	1 (16.7)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1.4)
<b>Vision Disorders</b>	<b>0 (0)</b>	<b>1 (16.7)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>0 (0)</b>	<b>1 (1.4)</b>
Blepharitis	0 (0)	1 (16.7)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1.4)

Source: Tables 14.2, 14.3, and 14.4, and Appendix 16.1.7

**Table 12.2.2-4: Number of Adverse Events By Dose Group and Body System; Active RWJXXX (All Dose Groups Combined) and Placebo**

Body System Adverse Event	Active RWJXXX (All Dose Groups) n (%)	Placebo n (%)	Total n (%)
Number of Adverse Events	58 (100)	13 (100)	71 (100)
<b>Body as a Whole</b>	<b>4 (6.9)</b>	<b>2 (15.4)</b>	<b>6 (8.5)</b>
Asthenia	1 (1.7)	0 (0)	1 (1.4)
Back Pain	0 (0)	1 (7.7)	1 (1.4)
Influenza-Like Symptoms	2 (3.4)	0 (0)	2 (2.8)
Temperature Changed Sensation	1 (1.7)	1 (7.7)	2 (2.8)
<b>Cardiovascular Disorders, General</b>	<b>1 (1.7)</b>	<b>0 (0)</b>	<b>1 (1.4)</b>
Hypotension	1 (1.7)	0 (0)	1 (1.4)
<b>Central &amp; Peripheral Nervous System Disorders</b>	<b>26 (44.8)</b>	<b>6 (46.2)</b>	<b>32 (45.1)</b>
Dizziness	8 (13.8)	3 (23.1)	11 (15.5)
Headache	3 (5.2)	1 (7.7)	4 (5.6)
Hypoaesthesia	10 (17.2)	1 (7.7)	11 (15.5)
Paraesthesia	5 (8.6)	1 (7.7)	6 (8.5)
<b>Gastro-intestinal System Disorders</b>	<b>5 (8.6)</b>	<b>3 (23.1)</b>	<b>8 (11.3)</b>
Abdominal Pain	1 (1.7)	0 (0)	1 (1.4)
Glossitis	0 (0)	1 (7.7)	1 (1.4)
Mouth Dry	3 (5.2)	0 (0)	3 (4.2)
Nausea	1 (1.7)	2 (15.4)	3 (4.2)
<b>Hearing &amp; Vestibular Disorders</b>	<b>1 (1.7)</b>	<b>0 (0)</b>	<b>1 (1.4)</b>
Ear Disorder Nos	1 (1.7)	0 (0)	1 (1.4)
<b>Musculo-skeletal System Disorders</b>	<b>2 (3.4)</b>	<b>0 (0)</b>	<b>2 (2.8)</b>
Arthralgia	1 (1.7)	0 (0)	1 (1.4)
Skeletal Pain	1 (1.7)	0 (0)	1 (1.4)
<b>Psychiatric Disorders</b>	<b>12 (20.7)</b>	<b>1 (7.7)</b>	<b>13 (18.3)</b>
Agitation	1 (1.7)	0 (0)	1 (1.4)
Euphoria	10 (17.2)	0 (0)	10 (14.1)
Nervousness	0 (0)	1 (7.7)	1 (1.4)
Somnolence	1 (1.7)	0 (0)	1 (1.4)
<b>Respiratory System Disorder</b>	<b>4 (6.9)</b>	<b>1 (7.7)</b>	<b>5 (7.0)</b>
Coughing	0 (0)	1 (7.7)	1 (1.4)
Dyspnoea	1 (1.7)	0 (0)	1 (1.4)
Sinusitis	1 (1.7)	0 (0)	1 (1.4)
Throat Tightness	2 (3.4)	0 (0)	2 (2.8)
<b>Secondary Terms</b>	<b>1 (1.7)</b>	<b>0 (0)</b>	<b>1 (1.4)</b>
Cyst Nos	1 (1.7)	0 (0)	1 (1.4)
<b>Skin &amp; Appendages Disorders</b>	<b>1 (1.7)</b>	<b>0 (0)</b>	<b>1 (1.4)</b>
Pruritis	1 (1.7)	0 (0)	1 (1.4)
<b>Vision Disorders</b>	<b>1 (1.7)</b>	<b>0 (0)</b>	<b>1 (1.4)</b>
Blepharitis	1 (1.7)	0 (0)	1 (1.4)

Source: Tables 14.2, 14.3, and 14.4, and Appendix 16.1.7

**Table 12.2.2-5: Number of Adverse Events by Dose and Relationship to Study Drug**

Relationship to Study Drug	Active RWJXXX Dose Group (mg)								Placebo
	100	250	400	750	1000	1250	1500	Total	
<b>Not related</b>	3	5	1	0	2	0	0	11	9
<b>Possible</b>	0	1	3	6	12	8	17	47	4

Source: Table 14.3 and Appendix 16.1.7